KRYS in “The Patent Cliff Sparks a Biotech Land Grab”
Krystal Biotech, Inc.
Commercial validation of its redosable gene-therapy platform makes Krystal a strategically scarce platform and product asset.
KRYS impact map — “The Patent Cliff Sparks a Biotech Land Grab”
How this story travels from the headline to KRYS’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading KRYS impact map…
Price history, marked with story events
Sep 8, 2020 – Sep 9, 2021 · 254 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
The Patent Cliff Sparks a Biotech Land Grab
Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
BULL side — Commercial validation of its redosable gene-therapy platform makes Krystal a strategically scarce platform and product asset.
Read the full The Patent Cliff Sparks a Biotech Land Grab story